Stocktoria

Emergent BioSolutions Inc. EBS

NYSE · stock · Pharmaceutical Preparations · website · IPO 2006-11-15 · LEI

Emergent BioSolutions Inc. statistics & valuation

Market cap$440.1M
P / E8.4×
P / S0.6×
P / B0.8×
P / FCF2.8×
Net margin7.1%
Return on equity10.1%
FCF margin21.1%
Net debt$384.3M
Net debt / EBITDA2×
Enterprise value USD$824.4M
EV / EBITDA4.2×
Earnings yield EBIT/EV12.1%
Return on capital8.4%
Graham number +205.2%$13.89

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($13.89); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
10.60% 14.70% 8.00% 4.90% 19.60% 12.40% -18.90% -72.50% -18.30% 7.10% 2016201720182019202020212022202320242025
Gross margin (%)
58.90% 50.30% 34.30% 30.30% 2016201720182019202020212022202320242025
Operating margin (%)
21.60% 22.20% 11.50% 10.30% 27.90% 19.20% -15.20% -69.20% -10.40% 13.50% 2016201720182019202020212022202320242025
Return on equity (%)
8.70% 9.10% 6.20% 5.00% 21.00% 13.60% -15.20% -117.10% -39.50% 10.10% 2016201720182019202020212022202320242025
Shares outstanding
49.3M 50.3M 51.4M 52.4M 53.8M 54.1M 50.1M 52.2M 54.3M 56.7M 2016201720182019202020212022202320242025
Net debt ($)
-$23.4M -$164.7M $696.6M $654.7M $264.2M $273.5M $771.2M $756.7M $600.5M $384.3M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
5.30% 7.70% 2.80% 2.30% 10.60% 7.40% -6.70% -41.70% -13.70% 4.00% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-4.40% 27.30% -3.90% 9.10% 25.40% 5.40% -13.40% -24.60% 3.40% 21.10% 2016201720182019202020212022202320242025
Debt / equity (×)
0.42× 0.01× 0.80× 0.76× 0.61× 0.53× 1.02× 1.34× 1.45× 1.13× 2016201720182019202020212022202320242025
EPS ($)
$1.13 $1.71 $1.22 $1.04 $5.67 $4.06 -$4.22 -$14.85 -$3.60 $0.93 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

Emergent BioSolutions Inc. trades at about 4.9× earnings — below its 10-year norm (10-year range 11.5×–53×, median 28.2×).

4.9× 53×

Shaded band = 10-year range (11.5×–53×); dot = today's 4.9×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross margin——30.3%34.3%50.3%58.9%————
Operating margin13.5%-10.4%-69.2%-15.2%19.2%27.9%10.3%11.5%22.2%21.6%
Net margin7.1%-18.3%-72.5%-18.9%12.4%19.6%4.9%8.0%14.7%10.6%
FCF margin21.1%3.4%-24.6%-13.4%5.4%25.4%9.1%-3.9%27.3%-4.4%
Return on assets4.0%-13.7%-41.7%-6.7%7.4%10.6%2.3%2.8%7.7%5.3%
Return on equity10.1%-39.5%-117.1%-15.2%13.6%21.0%5.0%6.2%9.1%8.7%
Debt / equity1.13×1.45×1.34×1.02×0.53×0.61×0.76×0.80×0.01×0.42×
Current ratio5.013.691.040.983.403.113.173.104.854.82

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.